NHS England, the royal colleges and institutional reversal

How did British medical institutions move from affirmation to caution, and which bodies still resist?

England’s institutional change did not begin with the Cass Review, but Cass gave it a formal evidential and administrative centre. For much of the previous decade, the NHS pathway for adolescents who met specialist criteria assumed that puberty suppression could precede masculinising or feminising hormones. NHS England’s 2016 policy provided for cross-sex hormones from “around” age 16 within the Tavistock’s Gender Identity Development Service (GIDS), while describing puberty blockers as part of the available treatment pathway after assessment and pubertal staging (NHS England, 2016). ([england

Background

England’s institutional change did not begin with the Cass Review, but Cass gave it a formal evidential and administrative centre. For much of the previous decade, the NHS pathway for adolescents who met specialist criteria assumed that puberty suppression could precede masculinising or feminising hormones. NHS England’s 2016 policy provided for cross-sex hormones from “around” age 16 within the Tavistock’s Gender Identity Development Service (GIDS), while describing puberty blockers as part of the available treatment pathway after assessment and pubertal staging (NHS England, 2016). ([england.nhs.uk](https://www.england.nhs.uk/commissioning/wp-content/uploads/sites/12/2016/08/clinical-com-pol-16046p.pdf))

This was not an entirely unqualified affirmation model: the 2016 policy acknowledged limited evidence for treatment below 16, possible irreversible effects of sex hormones and risks concerning growth, bone development and fertility. But, in practice, the institutional framework treated medical transition as an established option for selected adolescents. The centralised Tavistock service was the principal national provider, even as referrals rose steeply: the Royal College of Paediatrics and Child Health recorded fewer than 250 referrals in 2011–12 and more than 5,000 in 2021–22 (RCPCH, 2024). ([rcpch.ac.uk](https://www.rcpch.ac.uk/resources/gender-identity-services-advocacy-children-young-people?utm_source=openai))

The reversal was driven by four linked developments: the scale and changing character of referrals; concerns about clinical governance and follow-up; systematic evidence reviews commissioned by NHS England; and the decision to replace a single specialist service with regional, paediatric-led provision. The courts mattered, particularly in focusing public attention on consent, but they did not make the later clinical policy. In Bell v Tavistock, the High Court issued guidance in December 2020 suggesting that it was highly unlikely a child aged 13 or under could consent to puberty blockers and doubtful that most 14- and 15-year-olds could understand the relevant risks. The Court of Appeal set that guidance aside on 17 September 2021, holding that questions of Gillick competence were for clinicians rather than the court; the Supreme Court refused permission for a further appeal on 28 April 2022 (Bell v Tavistock, 2021; UK Supreme Court, 2022). ([rcpch.ac.uk](https://www.rcpch.ac.uk/resources/gender-identity-services-advocacy-children-young-people?utm_source=openai))

What the documents say

The Cass Review and the Tavistock replacement

The Cass Review’s final report of 10 April 2024 did not recommend abandoning care for children with gender-related distress. It recommended a different kind of care: holistic assessment, attention to mental health, neurodevelopmental conditions, family circumstances and safeguarding, better routine data, and services integrated with paediatrics and mental health rather than a stand-alone identity service (Cass Review, 2024). NHS England accepted that broad direction and described the new model as “fundamentally different” from the old service. ([england.nhs.uk](https://www.england.nhs.uk/long-read/nhs-englands-response-to-the-final-report-of-the-independent-review-of-gender-identity-services-for-children-and-young-people/?utm_source=openai))

GIDS closed on 31 March 2024 and new Children and Young People’s Gender Services began in London and the North West on 1 April. NHS England subsequently planned further regional centres. Since 1 September 2024, new referrals in England have generally required referral through secondary care, namely paediatric or mental-health services, rather than direct referral from primary care. This change places a conventional clinical assessment before entry to the specialist pathway (NHS England, 2024). ([england.nhs.uk](https://www.england.nhs.uk/long-read/children-and-young-peoples-gender-services-implementing-the-cass-review-recommendations/?utm_source=openai))

Puberty blockers

On 12 March 2024, before the Cass final report was published, NHS England adopted a policy that puberty-suppressing hormones were not available as a routine commissioning treatment for under-18s with gender incongruence or dysphoria. The stated reason was limited evidence concerning safety, risks, benefits and outcomes. Cass later recommended that puberty blockers should be available only within a research protocol after multidisciplinary assessment, with long-term follow-up (NHS England, 2024; Cass Review, 2024). ([england.nhs.uk](https://www.england.nhs.uk/publication/clinical-policy-puberty-suppressing-hormones/))

The Government then addressed private prescribing. Emergency restrictions began on 3 June 2024. On 11 December 2024, acting after advice from the Commission on Human Medicines, the Department of Health and Social Care made the restriction on new private supply for this purpose indefinite. Existing patients and patients using the medicines for other licensed or unrelated indications were treated differently. The order is scheduled for review in 2027 (DHSC, 2024). ([gov.uk](https://www.gov.uk/government/news/ban-on-puberty-blockers-to-be-made-indefinite-on-experts-advice?utm_source=openai))

Masculinising and feminising hormones

The position on sex hormones has moved more slowly but in the same direction. NHS England’s post-Cass 2024 policy still allowed restricted access for 16- and 17-year-olds with persistent gender dysphoria, subject to endorsement by a national multidisciplinary team. Cass advised “extreme caution” and a clear clinical rationale for treatment before 18. ([england.nhs.uk](https://www.england.nhs.uk/long-read/clinical-policy-prescribing-of-masculinising-and-feminising-hormones-for-children-and-adolescents-who-have-gender-incongruence-or-dysphoria-public-consultation-guide/))

In March 2026, NHS England paused that policy and opened a 90-day consultation proposing that masculinising and feminising hormones should no longer be routinely commissioned through the children’s service. The consultation document says subsequent evidence reviews found “very limited and weak” evidence supporting continued access for under-18s. It proposes continuity, on a case-by-case basis, for 16- and 17-year-olds already receiving NHS prescriptions, rather than abrupt withdrawal (NHS England, 2026). ([england.nhs.uk](https://www.england.nhs.uk/long-read/clinical-policy-prescribing-of-masculinising-and-feminising-hormones-for-children-and-adolescents-who-have-gender-incongruence-or-dysphoria-public-consultation-guide/))

The positions

The principal medical royal colleges have not formed a united resistance to the Cass framework. The Royal College of Psychiatrists welcomed the report as a comprehensive, evidence-based assessment, supported its emphasis on risk-benefit evaluation, data collection and a biopsychosocial approach, while stressing individualised and compassionate care (RCPsych, 2024). The Royal College of General Practitioners says it welcomed Cass and broadly supports the recommended model. The Academy of Medical Royal Colleges has urged implementation based on strong, current evidence and has delivered NHS-commissioned training for staff in the new services. ([rcpsych.ac.uk](https://www.rcpsych.ac.uk/news-and-features/latest-news/detail/2024/04/22/detailed-response-to-the-cass-review%27s-final-report?searchTerms=autism&utm_source=openai))

The RCPCH has also opposed a pause in Cass implementation. It has argued that delaying the replacement services would worsen already unacceptable waiting times and risk harm, while asking NHS England to consider emerging criticisms as it would in any other area of child health. Its position combines support for timely, respectful care with acceptance that the evidence and data deficits identified by Cass require repair (RCPCH, 2024). ([rcpch.ac.uk](https://www.rcpch.ac.uk/resources/gender-identity-services-advocacy-children-young-people?utm_source=openai))

The clearest institutional dissent has come from the British Medical Association, which is a doctors’ trade union and professional association rather than a royal college. In 2024, its Council commissioned a critique of Cass and the policy actions taken in Cass’s name. Its 2026 report accepted that the evidence for puberty suppression and sex hormones is limited, observational and uncertain; it also accepted the need for better data and multidisciplinary services. However, it argued that the uncertainty applies to benefits and harms, questioned whether restrictions were proportionate, and distinguished Cass’s recommendations from later statutory and commissioning decisions (BMA, 2026). ([cdn.intelligencebank.com](https://cdn.intelligencebank.com/eu/share/qMbw14/VEeb4/XeJDR/original/20260347%2BCass%2BReview%2Bupdate%2Bdocument))

Interpretation

Beyond Gender’s reading is that this is an institutional reversal because the NHS has returned to principles that should have governed paediatric medicine throughout: diagnosis before treatment, careful assessment of co-existing difficulties, meaningful informed consent, proportionate caution around potentially life-altering interventions, and audit of long-term outcomes. The striking point is not that the 2016 pathway contained no safeguards. It did. It is that a pathway founded on limited evidence became sufficiently normalised that its underlying evidential weakness was not confronted until referrals had multiplied and an independent review was commissioned.

The royal colleges’ responses matter because they show that “the medical establishment” is not simply split into affirming and gender-critical camps. The RCPsych, RCGP, RCPCH and Academy have broadly accepted the need for Cass-style reform, even where they emphasise dignity, prompt access and individual clinical care. The remaining resistance is more accurately described as resistance to the extent and pace of restrictions, especially the legal curbs on private prescribing and the prospect of removing routine access to sex hormones for under-18s.

The BMA’s later report is important but does not restore the old model. Its own review confirms that high-quality evidence is scarce and that long-term outcomes remain uncertain. Its disagreement is chiefly about how uncertainty should be managed. A gender-critical approach gives particular weight to the inability of a child to reverse lost pubertal development, fertility implications, bone-health concerns and the risk of committing a distressed young person to a medical pathway before the causes and course of that distress are properly understood.

Open questions

The first question is whether NHS England will adopt its 2026 proposal on masculinising and feminising hormones after considering consultation responses. Until a final policy is published, the 2024 policy remains paused rather than replaced. The second is whether the planned puberty-blocker research programme can be designed, approved and delivered in a way that answers the long-term questions Cass identified.

There are also service questions. Regional provision may be clinically sounder than the former single-provider model, but families need timely local mental-health and paediatric support while waiting. The success of the reversal should not be measured only by fewer prescriptions. It should be measured by whether children receive competent assessment, effective help for distress and co-occurring conditions, and transparent follow-up into adulthood.

Finally, institutions must distinguish clinical caution from hostility towards trans people. Respectful care, freedom from bullying and proper access to general healthcare are compatible with refusing to present uncertain medical interventions as settled, routine or inevitable.

On the UK timeline

Episodes on this subject

How Institutions LIE to Protect Themselves | Nick Wallis

"This is How Medical Institutions Became Captured!" | Joseph Figliolia

Collapse & Corruption in Ireland | Dr. Eoin Lenihan